Pfizer (INTC) Earns Coverage Optimism Rating of 1.02

Media stories about Pfizer (OTCMKTS:INTC) have trended somewhat positive recently, according to InfoTrie. The research group identifies negative and positive press coverage by monitoring more than 6,000 news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Pfizer earned a media sentiment score of 1.02 on their scale. InfoTrie also assigned news headlines about the company an news buzz score of 10 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company’s share price in the next few days.

Here are some of the media stories that may have impacted Pfizer’s analysis:

Pfizer stock opened at $49.31 on Friday. Pfizer has a 1-year low of $42.04 and a 1-year high of $57.60.

Pfizer (OTCMKTS:INTC) last posted its quarterly earnings results on Thursday, October 25th. The company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.15 by $0.25. The firm had revenue of $19.16 billion during the quarter, compared to analysts’ expectations of $18.11 billion.

COPYRIGHT VIOLATION WARNING: “Pfizer (INTC) Earns Coverage Optimism Rating of 1.02” was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US and international copyright and trademark laws. The original version of this piece of content can be read at

About Pfizer

Intel Corporation designs, manufactures, and sells computer, networking, data storage, and communication platforms worldwide. The company operates through Client Computing Group, Data Center Group, Internet of Things Group, Non-Volatile Memory Solutions Group, Programmable Solutions Group, and All Other segments.

Featured Story: Growth Stocks

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit